Flavopiridol's antiproliferative effects in glioblastoma multiforme | Zendy

Gozde Cobanoglu | Zendy; İrem Doğan | Zendy; Ayla Cihan Ozkan | Zendy; Abdullah Ekmekçi | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Flavopiridol's antiproliferative effects in glioblastoma multiforme

Author(s) -

Gozde Cobanoglu,

İrem Doğan,

Ayla Cihan Ozkan,

Abdullah Ekmekçi

Publication year - 2016

Publication title -

journal of cancer research and therapeutics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.475

H-Index - 39

eISSN - 0973-1482

pISSN - 1998-4138

DOI - 10.4103/0973-1482.172132

Subject(s) - cancer research , cyclin d1 , pten , protein kinase b , western blot , cell growth , apoptosis , kinase , biology , signal transduction , pi3k/akt/mtor pathway , chemistry , microbiology and biotechnology , cell cycle , biochemistry , gene

Glioblastoma multiforme (GBM) is largely refractory to surgical operation, radiotherapy, and chemotherapy in use today. Remaining lifetime accounting for the GBM-affected patients varies between 12 and 16 months generally. The most frequently altered genes in GBM are p53, epidermal growth factor receptor, PTEN, and cyclin-dependent kinase inhibitor 2A. Our aim is to investigate the antiproliferative and apoptotic effects of flavopiridol, a cyclin-dependent kinases and specific phosphokinase inhibitor, on glioblastoma cell lines having different genetic profiles: U87MG, U118MG, and T98G.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research